Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the rank-math domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/maiwald-test.dev5.yoyaba.tech/httpdocs/wp-includes/functions.php on line 6114
Royalty Pharma And Biohaven Announce Funding Agreement Totaling Up To $450 Million (Royalty Pharma) – Maiwald

All press coverage

Royalty Pharma and Biohaven Announce Funding Agreement Totaling up to $450 Million (Royalty Pharma)

6 Nov 2020

Biohaven will receive up to $250 million to fund zavegepant’s development in migraine and non-migraine indications
Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec^TM ODT and success-based milestone payments
Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise

Cooley acted as legal advisor to Biohaven on the transaction. Goodwin Procter, Jones Day and Maiwald acted as legal advisors to Royalty Pharma.

This text is a press release from Royalty Pharma.